Breakfast Technical Briefing on Biotech Stocks -- CEL-SCI, Amicus Therapeutics, Galena Biopharma, and Cleveland BioLabs

Monday, June 12, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, June 12, 2017 /PRNewswire/ -- has issued research reports on CEL-SCI Corp. (NYSEMKT:

CVM), Amicus Therapeutics Inc. (NASDAQ: FOLD), Galena Biopharma Inc. (NASDAQ: GALE), and Cleveland BioLabs Inc. (NASDAQ: CBLI). According to a report on Seeking Alpha, the Biotech sector, as represented by the NASDAQ Biotechnology Index ETF, remains
bound in a range between 280 and 300 level as it has been for nearly three months. However, the trading range has tightened, as the lower bound has risen from the 240 level in 2016. Daily Stock Tracker published free research reports on these stocks today at:


Vienna, Virginia headquartered CEL-SCI Corp.'s stock jumped 5.32%, finishing last Friday's trading session at $0.10. A total volume of 4.16 million shares was traded, which was above their three months average volume of 3.92 million shares. The Company's shares have gained 6.60% over the previous three months and 56.25% since the start of this year. The stock is trading above its 50-day moving average by 7.54%. Additionally, shares of CEL-SCI, which engages in the research and development of drugs and vaccines, have a Relative Strength Index (RSI) of 55.75.

On June 08th, 2017, CEL-SCI announced the publication of data from rheumatoid arthritis studies in Vaccine, a leading peer-reviewed journal for researchers interested in vaccines and vaccination. The paper is titled "An epitope-specific DerG-PG70 LEAPS vaccine modulates T cell responses and suppresses arthritis progression in two related murine models of rheumatoid arthritis". See our free and comprehensive research report on CVM at:

Amicus Therapeutics 

Shares in Cranbury, New Jersey headquartered Amicus Therapeutics Inc. ended at $8.46, down 1.97% from the last trading session. The stock recorded a trading volume of 1.78 million shares. The Company's shares have advanced 23.32% in the past month, 12.05% over the previous three months, and 70.22% since the start of this year. The stock is trading 12.20% and 22.20% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Amicus Therapeutics, which engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases, have an RSI of 61.01.

On June 07th, 2017, Amicus Therapeutics announced that John F. Crowley, Chairman and CEO, will participate in a corporate overview and fireside chat at the upcoming Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15th, 2017, at 10:40 a.m. PT in Rancho Palos Verdes, CA. A webcast of the presentation can be accessed under the Investors section of the Company's corporate website. FOLD free research report is just a click away at:

Galena Biopharma 

On Friday, shares in San Ramon, California-based Galena Biopharma Inc. recorded a trading volume of 478,490 shares. The stock rose 0.34%, closing the day at $0.56. The Company's shares are trading 5.23% below their 50-day moving average. Additionally, shares of Galena Biopharma, which develops hematology and oncology therapeutics that address unmet medical needs, have an RSI of 44.51. Sign up for your complimentary report on GALE at:

Cleveland BioLabs 

At the close of trading on Friday, shares in Buffalo, New York headquartered Cleveland BioLabs Inc. recorded a trading volume of 65,306 shares. The stock finished the session 1.40% lower at $3.51. The Company's shares have gained 4.46% in the past month, 115.34% in the previous three months, and 147.18% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 11.29% and 73.31%, respectively. Furthermore, shares of Cleveland BioLabs, which develops novel approaches to activate the immune system and address various medical needs in the US and the Russian Federation, have an RSI of 52.50.

On May 15th, 2017, Cleveland BioLabs reported financial results for Q1 ended March 31st, 2017. Net loss for Q1 2017 was $(1.7) million, excluding minority interests, compared to a net loss of $(0.7) million for Q1 2016. The Company had $13.1 million in cash, cash equivalents, and short-term investments, as of March 31st, 2017. Register for free on and download the latest research report on CBLI at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store